Phase 4
Completed N=20
Post-Market Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (CF-EAS-AC) for the Treatment of Symptomatic Atrial Fibrillation
Source: ClinicalTrials.gov NCT01196923 ↗Enrolled (actual)
20
Serious AEs
5.0%
Results posted
Jul 2016
Primary outcomePrimary: Acute Isolation of Pulmonary Veins. — 99 percent isolated pulmonary veins
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
The purpose of this study is to confirm the safety and effectiveness of the CardioFocus Endoscopic Ablation System with Adaptive Contact in the treatment of atrial fibrillation.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Acute Isolation of Pulmonary Veins. |
99 | — |
Eligibility Criteria
Inclusion Criteria
- Symptomatic, Paroxysmal Atrial Fibrillation (AF)
- 18 to 70 Years of age
- Others
Exclusion Criteria
- Generally good overall health as determined by multiple criteria
- Willing to participate in a study
- Others
Data sourced from ClinicalTrials.gov (NCT01196923). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.